In an era where drug-resistant infections pose a significant global health threat, the emergence of a new class of antibiotics marks a groundbreaking advancement in healthcare innovation.Kinvard Bio, a pioneering startup launched from Harvard University, is at the forefront of this antibiotic discovery, developing crucial treatments aimed at combating antimicrobial resistance.